Several Wall Street analysts updated their ratings and price targets for Twist Bioscience. While all maintained 'buy' ratings, price target adjustments were mixed, with some increasing and others decreasing, indicating varied near-term outlooks among analysts.
On November 14, 2026, four prominent Wall Street analysts issued updated research notes on Twist Bioscience. All analysts maintained their 'buy' ratings, signaling continued confidence in the company's long-term prospects. However, the price target adjustments were mixed: TD Cowen and Leerink Partners lowered their targets, while Baird and CCORF increased theirs. This divergence suggests varying short-term expectations regarding the company's valuation or growth trajectory among analysts. For traders, this indicates a lack of strong consensus on immediate price movement, making it a moderately impactful event. The key opportunity lies in understanding the underlying reasons for these target changes, which are not disclosed in this filing, to anticipate potential future stock performance.